Global CAR-T Cell Therapy Market
Global CAR-T Cell Therapy Market Zooms 6.2X to Touch Whopping USD 57 Billion by 2030
Published | 18 October 2024
Global CAR-T Cell Therapy Market is thriving due to increasing prevalence of cancer, a spurring demand for targeted therapies, and rapid adoption of technological advancements.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global CAR-T Cell Therapy Market size by value at USD 9.11 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global CAR-T Cell Therapy Market size to expand at a robust CAGR of 30.20% reaching a value of USD 56.80 billion in 2030. Global CAR-T Cell Therapy Market is driven by several key factors, including the increasing prevalence of cancer necessitates innovative treatments, boosting demand for CAR-T therapies. Advancements in CAR-T technology enhance treatment efficacy and safety. Growing demand for targeted and personalized therapies further propels market growth. Additionally, rising clinical trial activities and supportive regulatory frameworks encourage research and development, fostering market expansion.
Sample Request @ https://www.blueweaveconsulting.com/report/car-t-cell-therapy-market/report-sample
Opportunity – Expansion into other Indications
Global CAR-T Cell Therapy Market is growing with the expansion of new regulations. Initially focused on leukemia, CAR-T therapies are now being investigated for solid tumors and other diseases. Wide access enables patients to access and drives the market. Ongoing research and clinical trials are aimed at increasing the efficacy of CAR-T therapies for the conditions, driving market expansion.
Impact of Escalating Geopolitical Tensions on Global CAR-T Cell Therapy Market
Increasing geopolitical tensions could impact Global CAR-T Cell Therapy Market by disrupting supply chains and increasing input costs. Trade restrictions and political and economic instabilities could delay production and distribution. These challenges are forcing manufacturers to seek new sources and change processes, potentially increasing prices for consumers and affecting market growth.
Yescarta Holds Major Share of Global CAR-T Cell Therapy Market
The Axicabtagene Ciloleucel (Yescarta) segment accounts for the largest market share of Global CAR-T Cell Therapy Market by drug indication, due to its high efficacy in treating certain types of blood cancers, particularly diffuse large B-cell lymphoma (DLBCL). Yescarta's success in clinical trials and its widespread adoption in various regions contribute to its leading position in the market. The other major drug indication segments in Global CAR-T Cell Therapy Market include Brexucabtagene Autoleucel (Tecartus), Ciltacabtagene Autoleucel (Carvykti), Idecabtagene Vicleucel (Abecma), Lisocabtagene Maraleucel (Breyanzi), and Tisagenlecleucel (Kymriah).
Competitive Landscape
Global CAR-T Cell Therapy Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Bristol-Myers Squibb, Sorrento Therapeutics, Inc., Celgene Corporation, Merck & Co., Inc., Novartis AG, Celyad Oncology, Juno Therapeutics, Inc., Autolus Therapeutics, Cellectis, Miltenyi Biotech, Intellia Therapeutics, and Pfizer, Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global CAR-T Cell Therapy Market.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global CAR-T Cell Therapy Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technological trends in Global CAR-T Cell Therapy Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the Market.
Scope of the Report
Attributes |
Details |
Years Considered |
Historical Data – 2019–2023 |
Base Year – 2023 |
|
Estimated Year – 2024 |
|
Forecast Period – 2024–2030 |
|
Facts Covered |
Revenue in USD Billion |
Market Coverage |
North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA) |
Product/Service Segmentation |
Drug Indication, Indication, End User, Region |
Key Players |
Bristol-Myers Squibb, Sorrento Therapeutics, Inc., Celgene Corporation, Merck & Co., Inc., Novartis AG, Celyad Oncology, Juno Therapeutics, Inc., Autolus Therapeutics, Cellectis, Miltenyi Biotech, Intellia Therapeutics, Pfizer, Inc. |
About Us
BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive Market research reports by analyzing both qualitative and quantitative data to boost the performance of your business solutions. BlueWeave has built its reputation by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.
Contact Us:
BlueWeave Consulting & Research Pvt Ltd
+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662
Get Help
Related Report
Publish Date: October 2024
An increasing number of cancer incidents, a spurring demand for targeted and personalized therapies, adoption of advancements in CAR-T technology, and growing number of clinical trial programs are expected to drive Global CAR-T Cell Therapy Market during the forecast period between 2024 and 2030.
Relevant Press Releases
- Global External Defibrillator Market to Reach USD 7.5 Billion by 2028
- Global Molecular Diagnostics Market Flourishing at Robust 11.3% CAGR during Forecast Period
- Singapore Diagnostic Labs Market Size Booming to Reach USD 3.6 Billion by 2030
- Middle East and Africa Radiotherapy Market Size Set to Expand at Significant CAGR of 4.75% to Touch USD 265.02 Million by 2030
- Saudi Arabia Diagnostic Imaging Market to Grow at 9.2% during Forecast Period